STEM CELL THERAPY AND C.O.P.D.
( CHRONIC OBSTRUTIVE PULMONARY DISEASE )
Patients with chronic obstructive lung disease have marked shortness of breath, limitations in life style because of easy fatigue, inability to walk except for short distances, problems sleeping at night even in a semi-sitting position, susceptible to bronchitis and pneumonia, often requiring oxygen twenty four hours a day. Patients are monitored by spirometry, pulmonary function tests and pulse ox tests.
Treatment consists of inhalers such as albuterol(or Xopenex), Pulmocort for short term use for severe shortness of breath and Spireva and Advair for long term control. In recent times a new long term bronchodilator Brovana administered with a nebulizer can give twelve hours of relief and could replace xopenex or albuterol in some patients.
Additional treatment are the use of special inhalers that deliver medications move deeply into the lung tissues; breathing exercises, chest tapping to loosen mucus plugs in the bronchi and bronchioles and postural drainage.
In recent times treatments with stem cells have been used in attempts to greatly improve lung function. The first step is isolating stem cells from the patient?s own blood or bone marrow. It takes approximately seven days to isolate and separate out stem cells although a more rapid procedure has been introduced that isolates the stem cells in less than one day. The number of stem cells are modest in numbers but are expanded in the laboratory to many millions, These cells are called autologous stem cells and are then infused intravenously into the patient. Additional factors are administered to insure the engraftment and survival of these autologous stem cells. The patient will also receive these autologous stem cells plus retinoic acid and glutathione by nebulizer. Patients receiving this form of treatment have shown improvement in their endurance, exercise tolerance, less dependence on oxygen day or night and less shortness of breath.
Recent research studies have shown that there are strong immunological characteristics to COPD. Pro-inflammatory mediators lead to chronic inflammation and autoimmune antibodies that destroy lung tissue. This is all initiated with the over activity of T lymphocytes.
This leads to production of interferon gamma, interleukins IL-1B, IL-6, IL-6, IL-13 , tumor necrosis factor and leukotrienes. Therapeutic strategies aimed at these chemokines have been proposed.
Following treatment some specialized supplements for DNA protection; improvement of mitochondrial function in the pulmonary cells; stem cell oral stimulants will be given.
Following treatment follow-up blood gases, pulse ox, pulmonary function tests and chest x-rays will be done. Evaluation of patient?s tolerance to physical activity; less dependence on the use of oxygen will be determined; general energy level of the patient; ability to sleep more flat in bed with less or no use of oxygen at night will be determined.
This may be all the patient may need for stem cell treatment although it is possible that a repeat treatment in four to six months may be considered for the patient.
Some patients may elect to go on to the second stage of treatment with the use of pulmonary stem cells derived from umbilical cord blood. These pulmonary cells are grown in culture with special nutrients and growth factors to program them to become pulmonary stem cells. This culture method usually requires about three weeks in time. Patients are given progenitor cells, pulmonary stem cells and human stem cell growth factors intravenously over a one hour plus period. In addition pulmonary stem cells and retinoic acid is given by nebulizer.
Post stem therapy program medications are then given to the patient to be taken for six months. Patients who travel a distance whether by plane or automobile to receive this treatment should have received a pneumovax and flu vaccine within the last three years. In severe cases of emphysema and COPD the use of short term inhalers and prophylactic antibiotics may be advisable to prevent secondary infections because of fatigue of traveling; exposure to secondary infections; and decreased immune system. Eat lots of broccoli and
apples that are rich in anti-oxidants. We recommend the use of N-acetyl cysteine 600 mg. daily, Vitamin A 10,000 i.u, Vitamin B-12 1500 mg, Alpha lipoic acid 200 mg., Selenium 200 mg., Co-Q10 100 mg., Stem Cell Advance.
( CHRONIC OBSTRUTIVE PULMONARY DISEASE )
Patients with chronic obstructive lung disease have marked shortness of breath, limitations in life style because of easy fatigue, inability to walk except for short distances, problems sleeping at night even in a semi-sitting position, susceptible to bronchitis and pneumonia, often requiring oxygen twenty four hours a day. Patients are monitored by spirometry, pulmonary function tests and pulse ox tests.
Treatment consists of inhalers such as albuterol(or Xopenex), Pulmocort for short term use for severe shortness of breath and Spireva and Advair for long term control. In recent times a new long term bronchodilator Brovana administered with a nebulizer can give twelve hours of relief and could replace xopenex or albuterol in some patients.
Additional treatment are the use of special inhalers that deliver medications move deeply into the lung tissues; breathing exercises, chest tapping to loosen mucus plugs in the bronchi and bronchioles and postural drainage.
In recent times treatments with stem cells have been used in attempts to greatly improve lung function. The first step is isolating stem cells from the patient?s own blood or bone marrow. It takes approximately seven days to isolate and separate out stem cells although a more rapid procedure has been introduced that isolates the stem cells in less than one day. The number of stem cells are modest in numbers but are expanded in the laboratory to many millions, These cells are called autologous stem cells and are then infused intravenously into the patient. Additional factors are administered to insure the engraftment and survival of these autologous stem cells. The patient will also receive these autologous stem cells plus retinoic acid and glutathione by nebulizer. Patients receiving this form of treatment have shown improvement in their endurance, exercise tolerance, less dependence on oxygen day or night and less shortness of breath.
Recent research studies have shown that there are strong immunological characteristics to COPD. Pro-inflammatory mediators lead to chronic inflammation and autoimmune antibodies that destroy lung tissue. This is all initiated with the over activity of T lymphocytes.
This leads to production of interferon gamma, interleukins IL-1B, IL-6, IL-6, IL-13 , tumor necrosis factor and leukotrienes. Therapeutic strategies aimed at these chemokines have been proposed.
Following treatment some specialized supplements for DNA protection; improvement of mitochondrial function in the pulmonary cells; stem cell oral stimulants will be given.
Following treatment follow-up blood gases, pulse ox, pulmonary function tests and chest x-rays will be done. Evaluation of patient?s tolerance to physical activity; less dependence on the use of oxygen will be determined; general energy level of the patient; ability to sleep more flat in bed with less or no use of oxygen at night will be determined.
This may be all the patient may need for stem cell treatment although it is possible that a repeat treatment in four to six months may be considered for the patient.
Some patients may elect to go on to the second stage of treatment with the use of pulmonary stem cells derived from umbilical cord blood. These pulmonary cells are grown in culture with special nutrients and growth factors to program them to become pulmonary stem cells. This culture method usually requires about three weeks in time. Patients are given progenitor cells, pulmonary stem cells and human stem cell growth factors intravenously over a one hour plus period. In addition pulmonary stem cells and retinoic acid is given by nebulizer.
Post stem therapy program medications are then given to the patient to be taken for six months. Patients who travel a distance whether by plane or automobile to receive this treatment should have received a pneumovax and flu vaccine within the last three years. In severe cases of emphysema and COPD the use of short term inhalers and prophylactic antibiotics may be advisable to prevent secondary infections because of fatigue of traveling; exposure to secondary infections; and decreased immune system. Eat lots of broccoli and
apples that are rich in anti-oxidants. We recommend the use of N-acetyl cysteine 600 mg. daily, Vitamin A 10,000 i.u, Vitamin B-12 1500 mg, Alpha lipoic acid 200 mg., Selenium 200 mg., Co-Q10 100 mg., Stem Cell Advance.